2680 related articles for article (PubMed ID: 21535989)
1. Biological aspects of altered bone remodeling in multiple myeloma and possibilities of pharmacological intervention.
Kupisiewicz K
Dan Med Bull; 2011 May; 58(5):B4277. PubMed ID: 21535989
[TBL] [Abstract][Full Text] [Related]
2. Pulse treatment with the proteasome inhibitor bortezomib inhibits osteoclast resorptive activity in clinically relevant conditions.
Boissy P; Andersen TL; Lund T; Kupisiewicz K; Plesner T; Delaissé JM
Leuk Res; 2008 Nov; 32(11):1661-8. PubMed ID: 18394701
[TBL] [Abstract][Full Text] [Related]
3. Resveratrol inhibits myeloma cell growth, prevents osteoclast formation, and promotes osteoblast differentiation.
Boissy P; Andersen TL; Abdallah BM; Kassem M; Plesner T; Delaissé JM
Cancer Res; 2005 Nov; 65(21):9943-52. PubMed ID: 16267019
[TBL] [Abstract][Full Text] [Related]
4. Response to bortezomib and activation of osteoblasts in multiple myeloma.
Zangari M; Yaccoby S; Cavallo F; Esseltine D; Tricot G
Clin Lymphoma Myeloma; 2006 Sep; 7(2):109-14. PubMed ID: 17026821
[TBL] [Abstract][Full Text] [Related]
5. Myeloma cell-induced disruption of bone remodelling compartments leads to osteolytic lesions and generation of osteoclast-myeloma hybrid cells.
Andersen TL; Søe K; Sondergaard TE; Plesner T; Delaisse JM
Br J Haematol; 2010 Feb; 148(4):551-61. PubMed ID: 19919653
[TBL] [Abstract][Full Text] [Related]
6. CCR1 chemokines promote the chemotactic recruitment, RANKL development, and motility of osteoclasts and are induced by inflammatory cytokines in osteoblasts.
Yu X; Huang Y; Collin-Osdoby P; Osdoby P
J Bone Miner Res; 2004 Dec; 19(12):2065-77. PubMed ID: 15537451
[TBL] [Abstract][Full Text] [Related]
7. Cellular and molecular effects of growth hormone and estrogen on human bone cells.
Kassem M
APMIS Suppl; 1997; 71():1-30. PubMed ID: 9357492
[TBL] [Abstract][Full Text] [Related]
8. The proteasome inhibitor bortezomib stimulates osteoblastic differentiation of human osteoblast precursors via upregulation of vitamin D receptor signalling.
Kaiser MF; Heider U; Mieth M; Zang C; von Metzler I; Sezer O
Eur J Haematol; 2013 Apr; 90(4):263-72. PubMed ID: 23311753
[TBL] [Abstract][Full Text] [Related]
9. Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma.
Breitkreutz I; Raab MS; Vallet S; Hideshima T; Raje N; Mitsiades C; Chauhan D; Okawa Y; Munshi NC; Richardson PG; Anderson KC
Leukemia; 2008 Oct; 22(10):1925-32. PubMed ID: 18596740
[TBL] [Abstract][Full Text] [Related]
10. Bone-resorbing cells in multiple myeloma: osteoclasts, myeloma cell polykaryons, or both?
Silvestris F; Ciavarella S; De Matteo M; Tucci M; Dammacco F
Oncologist; 2009 Mar; 14(3):264-75. PubMed ID: 19286760
[TBL] [Abstract][Full Text] [Related]
11. Osteoprogenitor differentiation is not affected by immunomodulatory thalidomide analogs but is promoted by low bortezomib concentration, while both agents suppress osteoclast differentiation.
Munemasa S; Sakai A; Kuroda Y; Okikawa Y; Katayama Y; Asaoku H; Kubo T; Shimose S; Kimura A
Int J Oncol; 2008 Jul; 33(1):129-36. PubMed ID: 18575758
[TBL] [Abstract][Full Text] [Related]
12. Secreted frizzled-related protein-1 inhibits RANKL-dependent osteoclast formation.
Häusler KD; Horwood NJ; Chuman Y; Fisher JL; Ellis J; Martin TJ; Rubin JS; Gillespie MT
J Bone Miner Res; 2004 Nov; 19(11):1873-81. PubMed ID: 15476588
[TBL] [Abstract][Full Text] [Related]
13. The effect of novel anti-myeloma agents on bone metabolism of patients with multiple myeloma.
Terpos E; Dimopoulos MA; Sezer O
Leukemia; 2007 Sep; 21(9):1875-84. PubMed ID: 17611556
[TBL] [Abstract][Full Text] [Related]
14. Pathophysiology of multiple myeloma bone disease.
Lentzsch S; Ehrlich LA; Roodman GD
Hematol Oncol Clin North Am; 2007 Dec; 21(6):1035-49, viii. PubMed ID: 17996587
[TBL] [Abstract][Full Text] [Related]
15. Proteasome inhibition aggravates tumor necrosis factor-mediated bone resorption in a mouse model of inflammatory arthritis.
Polzer K; Neubert K; Meister S; Frey B; Baum W; Distler JH; Gückel E; Schett G; Voll RE; Zwerina J
Arthritis Rheum; 2011 Mar; 63(3):670-80. PubMed ID: 21360496
[TBL] [Abstract][Full Text] [Related]
16. The proteasome inhibitor, bortezomib suppresses primary myeloma and stimulates bone formation in myelomatous and nonmyelomatous bones in vivo.
Pennisi A; Li X; Ling W; Khan S; Zangari M; Yaccoby S
Am J Hematol; 2009 Jan; 84(1):6-14. PubMed ID: 18980173
[TBL] [Abstract][Full Text] [Related]
17. Prostaglandin E2 stimulates osteoclast-like cell formation and bone-resorbing activity via osteoblasts: role of cAMP-dependent protein kinase.
Kaji H; Sugimoto T; Kanatani M; Fukase M; Kumegawa M; Chihara K
J Bone Miner Res; 1996 Jan; 11(1):62-71. PubMed ID: 8770698
[TBL] [Abstract][Full Text] [Related]
18. The effects of bortezomib on bone disease in patients with multiple myeloma.
Mohty M; Malard F; Mohty B; Savani B; Moreau P; Terpos E
Cancer; 2014 Mar; 120(5):618-23. PubMed ID: 24249482
[TBL] [Abstract][Full Text] [Related]
19. Recruitment of new osteoblasts and osteoclasts is the earliest critical event in the pathogenesis of human multiple myeloma.
Bataille R; Chappard D; Marcelli C; Dessauw P; Baldet P; Sany J; Alexandre C
J Clin Invest; 1991 Jul; 88(1):62-6. PubMed ID: 2056131
[TBL] [Abstract][Full Text] [Related]
20. A comparison between the effects of hydrophobic and hydrophilic statins on osteoclast function in vitro and ovariectomy-induced bone loss in vivo.
Hughes A; Rogers MJ; Idris AI; Crockett JC
Calcif Tissue Int; 2007 Nov; 81(5):403-13. PubMed ID: 17982704
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
